Tweet
Exp Hematol. 2012 Oct 26. pii: S0301-472X(12)00442-0. doi: 10.1016/j.exphem.2012.10.011. [Epub ahead of print]
Erythropoietin treatment is associated with an augmented immune response to the influenza vaccine in hematologic patients.
Oster HS, Prutchi-Sagiv S, Halutz O, Shabtai E, Hoffman M, Neumann D, Mittelman M.
Source
Department of Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv, Tel Aviv University, Sackler Faculty of Medicine.
Abstract
The objective of this study is to examine whether treatment with recombinant human erythropoietin (rHuEPO), previously found to be associated with a positive impact on cell-mediated immunity, and humoral immunity (Hepatitis B vaccine), is associated with an improved response to the seasonal influenza (flu) vaccine. Three groups received flu vaccine: healthy controls, hematologic patients not treated with rHuEPO ("No EPO" group), and hematologic patients receiving rHuEPO for their anemia ("EPO"). Anti-flu Ab titer was measured (complement fixation test) from blood samples drawn prior to and approximately 3-4 weeks, 7-8 weeks and 4 months post vaccination. Nineteen healthy subjects were compared to 17 No EPO and 17 EPO patients. Mean ages were 59.5, 61.3, and 73.1 respectively; (EPO patients were older, p=0.005). In the healthy group the percentage of those sustaining only a partial (2-fold) response, a strong (4-fold or greater) response and an overall response (combined partial and strong responses) were 31.6%, 57.9%, and 89.5% respectively. In the No EPO group respective values were: 35.3%, 17.6%, and 52.9%. EPO group results were similar to those of the healthy controls: 23.5%, 58.8%, 82.4% respectively. P=0.016 (EPO vs No EPO). Conclusions: 1) Hematologic patients (NoEPO group) respond poorly to the flu vaccine, compared to healthy subjects. 2) rHuEPO treatment is associated with an improved immune response to the flu vaccine in hematologic patients, with titers similar to those of healthy subjects.
Copyright ? 2012 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
PMID:
23107605
[PubMed - as supplied by publisher]
Erythropoietin treatment is associated with an augmented immune response to the influenza vaccine in hematologic patients.
Oster HS, Prutchi-Sagiv S, Halutz O, Shabtai E, Hoffman M, Neumann D, Mittelman M.
Source
Department of Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv, Tel Aviv University, Sackler Faculty of Medicine.
Abstract
The objective of this study is to examine whether treatment with recombinant human erythropoietin (rHuEPO), previously found to be associated with a positive impact on cell-mediated immunity, and humoral immunity (Hepatitis B vaccine), is associated with an improved response to the seasonal influenza (flu) vaccine. Three groups received flu vaccine: healthy controls, hematologic patients not treated with rHuEPO ("No EPO" group), and hematologic patients receiving rHuEPO for their anemia ("EPO"). Anti-flu Ab titer was measured (complement fixation test) from blood samples drawn prior to and approximately 3-4 weeks, 7-8 weeks and 4 months post vaccination. Nineteen healthy subjects were compared to 17 No EPO and 17 EPO patients. Mean ages were 59.5, 61.3, and 73.1 respectively; (EPO patients were older, p=0.005). In the healthy group the percentage of those sustaining only a partial (2-fold) response, a strong (4-fold or greater) response and an overall response (combined partial and strong responses) were 31.6%, 57.9%, and 89.5% respectively. In the No EPO group respective values were: 35.3%, 17.6%, and 52.9%. EPO group results were similar to those of the healthy controls: 23.5%, 58.8%, 82.4% respectively. P=0.016 (EPO vs No EPO). Conclusions: 1) Hematologic patients (NoEPO group) respond poorly to the flu vaccine, compared to healthy subjects. 2) rHuEPO treatment is associated with an improved immune response to the flu vaccine in hematologic patients, with titers similar to those of healthy subjects.
Copyright ? 2012 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
PMID:
23107605
[PubMed - as supplied by publisher]
